Retatrutide vs Mazdutide: Multi-Receptor Agonists Compared

The Race Beyond Semaglutide

The GLP-1 drug landscape is moving faster than almost any other area of pharmaceutical research. Semaglutide became the reference standard. Tirzepatide (GIP/GLP-1 dual agonist) beat it. Now retatrutide and mazdutide are competing to go even further — targeting more receptors, producing greater metabolic effects, and potentially addressing conditions beyond obesity.

Both retatrutide and mazdutide represent the multi-receptor agonist approach: targeting multiple metabolic hormone systems simultaneously to produce effects that no single receptor agonist can achieve alone.

Retatrutide (LY3437943): Triple GIP/GLP-1/Glucagon Agonist

Retatrutide, developed by Eli Lilly, is the most advanced triple agonist in clinical development. It activates three receptors simultaneously:

• GLP-1 receptor: Reduces appetite, slows gastric emptying, increases insulin secretion
• GIP receptor: Enhances insulin response, may improve the tolerability of GLP-1 effects
• Glucagon receptor: Increases energy expenditure through thermogenesis, promotes fat mobilization, reduces liver fat

The addition of the glucagon receptor component is what sets retatrutide apart from tirzepatide. Phase 2 trial results (published in NEJM 2023) showed extraordinary results:

• Average weight loss of 17.5% at 24 weeks (highest dose group)
• Up to 24.2% weight loss in some participants over the trial period
• Significant reductions in liver fat, triglycerides, and waist circumference
• Dose-dependent effects with generally acceptable safety profile

These numbers exceed anything previously seen in obesity pharmacology. Retatrutide is currently in Phase 3 trials.

View Retatrutide →

Mazdutide (IBI362): Dual GLP-1/Glucagon Agonist

Mazdutide, developed by Innovent Biologics, is a dual GLP-1/glucagon receptor agonist — similar to survodutide in its receptor profile. Unlike retatrutide, it does not include GIP receptor activity.

Mazdutide has shown strong results in Chinese clinical trials, where it was initially developed for type 2 diabetes management. Key findings:

• Phase 2 obesity trial showed approximately 11-14% weight loss over 24 weeks
• Significant HbA1c reduction in type 2 diabetes trials
• Strong liver fat reduction — the glucagon component drives liver fat mobilization more effectively than GLP-1 alone
• Currently in Phase 3 trials in China; global trials underway

Mazdutide’s weight loss numbers are lower than retatrutide but compare favorably with semaglutide, and its liver fat effects may make it particularly interesting for NASH/MAFLD research.

View Mazdutide →

Side-by-Side Comparison

Research Significance of the Triple Agonist Approach

Retatrutide’s triple agonism represents a landmark in metabolic peptide research. By combining GIP-enhanced insulin sensitization with GLP-1’s appetite suppression and glucagon’s thermogenic and fat-mobilizing effects, it achieves additive benefits that push past what any single or dual pathway can deliver.

The research implications extend beyond obesity:

• NASH/MAFLD: The glucagon component provides direct liver fat reduction not seen with GLP-1 alone
• Cardiovascular risk: Magnitude of weight loss, triglyceride reduction, and metabolic improvement suggest strong CV risk reduction potential
• Type 2 diabetes: Triple agonism may achieve superior glycemic control with additional metabolic benefits

For researchers studying metabolic disease, both retatrutide and mazdutide represent the current frontier of peptide pharmacology — the benchmark against which future metabolic compounds will be measured.

Written by the NorthPeptide Research Team